A promising new drug therapy developed by Ohio State neurosurgeon Shahid Nimjee, MD, PhD, may hold the key to providing effective treatment to stroke victims and solving one of the biggest complications in strokes: bleeding.
Press Releases
-Phase 2-Ready Drug Candidate Offers Potential to Greatly Broaden the Acute Ischemic Stroke Population Who Can Benefit from Thrombolytic Therapy- …
-BB-031, a potential rapid onset, short-acting and reversible thrombolytic, targets von Willebrand Factor, a key structural component of thrombi and …
Columbus, OH: January 31, 2023: Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, …
Funding to support development of the first reversible thrombolytic therapy for acute ischemic stroke Columbus, OH –(BUSINESS WIRE)—Basking Biosciences, Inc. …
Publications
isth 2022
MDPI
AHA Journals